On May 8, 2004, Novo Nordisk received the Angel Award for its dedication to improving the lives of individuals with diabetes and its unwavering focus on treating and preventing diabetes worldwide. The award was presented at the Los Angeles Chapter of the Juvenile Diabetes Research Foundation's (JDRF) annual gala benefiting the Stem Cell Research Fund.
Along with its work with the JDRF, Novo Nordisk is active in a number of initiatives as part of the company's dedication to social responsibility. The company recently launched the Diabetes Aware campaign with the Entertainment Industry Foundation to educate Americans about the importance of detection, monitoring, and proper management of this chronic, progressive disease.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs